Orthocell (ASX:OCC) was granted a license by the Food and Drug Administration of Thailand to start selling its Remplir nerve repair collagen wrap in the country, according to a Monday Australian bourse filing.
Thailand's nerve repair market has an estimated value of $84 million. It plans to appoint a local on-the-ground specialist distributor.
The firm said it leveraged an expedited registration pathway available for medical devices already approved by the Health Sciences Authority in Singapore.
The firm is considering other potential markets in Asia-Pacific, including Taiwan, Vietnam, Indonesia, and the Philippines.
The company's shares gained about 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.